Unknown

Dataset Information

0

Blood Transcriptome Profiling Links Immunity to Disease Severity in Myotonic Dystrophy Type 1 (DM1).

ABSTRACT: The blood transcriptome was examined in relation to disease severity in type I myotonic dystrophy (DM1) patients who participated in the Observational Prolonged Trial In DM1 to Improve QoL- Standards (OPTIMISTIC) study. This sought to (a) ascertain if transcriptome changes were associated with increasing disease severity, as measured by the muscle impairment rating scale (MIRS), and (b) establish if these changes in mRNA expression and associated biological pathways were also observed in the Dystrophia Myotonica Biomarker Discovery Initiative (DMBDI) microarray dataset in blood (with equivalent MIRS/DMPK repeat length). The changes in gene expression were compared using a number of complementary pathways, gene ontology and upstream regulator analyses, which suggested that symptom severity in DM1 was linked to transcriptomic alterations in innate and adaptive immunity associated with muscle-wasting. Future studies should explore the role of immunity in DM1 in more detail to assess its relevance to DM1.

SUBMITTER: Nieuwenhuis S 

PROVIDER: S-EPMC8954763 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Blood Transcriptome Profiling Links Immunity to Disease Severity in Myotonic Dystrophy Type 1 (DM1).

Nieuwenhuis Sylvia S   Widomska Joanna J   Blom Paul P   't Hoen Peter-Bram A C PAC   van Engelen Baziel G M BGM   Glennon Jeffrey C JC   On Behalf Of The Optimistic Consortium  

International journal of molecular sciences 20220312 6

The blood transcriptome was examined in relation to disease severity in type I myotonic dystrophy (DM1) patients who participated in the Observational Prolonged Trial In DM1 to Improve QoL- Standards (OPTIMISTIC) study. This sought to (a) ascertain if transcriptome changes were associated with increasing disease severity, as measured by the muscle impairment rating scale (MIRS), and (b) establish if these changes in mRNA expression and associated biological pathways were also observed in the Dys  ...[more]

Similar Datasets

Genomics Blood transcriptome profiling links immunity to disease severity in myotonic dystrophy type 1 (DM1).
| EGAS00001006926 | EGA
Unknown Delay of EGF-Stimulated EGFR Degradation in Myotonic Dystrophy Type 1 (DM1).
| S-EPMC9562898 | biostudies-literature
Unknown Targeting toxic RNAs that cause myotonic dystrophy type 1 (DM1) with a bisamidinium inhibitor.
| S-EPMC4015652 | biostudies-literature
Unknown Manumycin A corrects aberrant splicing of Clcn1 in myotonic dystrophy type 1 (DM1) mice.
| S-EPMC3701899 | biostudies-literature
Unknown Fluid Biomarkers of Central Nervous System (CNS) Involvement in Myotonic Dystrophy Type 1 (DM1).
| S-EPMC9917343 | biostudies-literature
Unknown Vorinostat Improves Myotonic Dystrophy Type 1 Splicing Abnormalities in DM1 Muscle Cell Lines and Skeletal Muscle from a DM1 Mouse Model.
| S-EPMC9964082 | biostudies-literature
Unknown Development of a genomic DNA reference material panel for myotonic dystrophy type 1 (DM1) genetic testing.
| S-EPMC3699699 | biostudies-literature
Unknown Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1).
| S-EPMC3764231 | biostudies-literature
Transcriptomics RNA-seq of skeletal muscle model for myotonic dystrophy type 1 (DM1)
2021-08-19 | GSE181895 | GEO
Unknown Predictors of prognosis in type 1 myotonic dystrophy (DM1): longitudinal 18-years experience from a single center.
| S-EPMC7711325 | biostudies-literature